Novartis’s Enerzair Breezhaler (QVM149) indacaterol / glycopyrronium / mometasone furoate DPI has been approved by the EC for the treatment of asthma, the company said. The inhaler can now be marketed with an optional Propeller Health sensor and mobile app throughout the EU, and in the UK, Iceland, Norway, and Liechtenstein. The EMA’s Committee for Medicinal Products for Human Use recommended approval of Enerzair Breezhaler at its April 2020 meeting.
Sosei Heptares announced that it is due a $5 million milestone payment from Novartis under a 2005 licensing agreement for glycopyrronium. Vectura also said that it is due a $5 million milestone payment under that agreement as well as $1.25 million for the recent approval in Japan. Enerzair Breezhaler has also recently been approved in Canada.
Novartis Pharmaceuticals Head of Global Marketing Rod Wooten said, “Novartis is working to reimagine medicine for people with uncontrolled asthma, who find it a challenge to achieve effective symptom and exacerbation control. The approval of Enerzair Breezhaler with sensor and app in the EU is an example of our commitment to utilize data and digital offerings to make asthma control an achievable goal for patients and physicians.”
Propeller Health CEO David Van Sickle commented, “Our collaboration with Novartis to co-package Propeller with Enerzair Breezhaler is the first time a pharmaceutical company and digital health company have worked together to package a digital health platform with an asthma medication. The ability to prescribe a maintenance medication with Propeller will make it easier for healthcare professionals to engage their patients in self-management.”
Read the Novartis press release.
Read the Propeller Health press release.
Read the Sosei Heptares press release.
Read the Vectura press release.
